COPD Trial, Recruiting NCT00576069 Sponsor: Gelb, Arthur F., M.D. Condition: COPD
Back to Copd

COPD Trial, Recruiting

NCT00576069
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are currently non-smokers and have smoked less than 10 pack-years in total throughout their lifetime
  • People who have asthma that is stable and being treated with medication
  • People between the ages of 12 and 95 years old
  • People whose lung function test results, taken after using a standard dose of albuterol (a common asthma reliever inhaler), show specific patterns of airflow limitation (confirm with trial site for exact test values)

Who may not be able to join:

  • People who are currently pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Arthur F Gelb, MD, Arthur F Gelb Medical Corporation

Phone: 562-633-2204

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Gelb, Arthur F., M.D.
Registry
ClinicalTrials.gov
Start date
25 October 2007
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

use exhaled nitric oxide as a surrogate marker of large airway vs small airway/lung inflammation following various doses of inhaled corticosteroids; determine site of airflow limitation, whether predominantly large and /or small airways using expiratory flow volume curves obtained before and after asthmatics breathe a 80% helium-20% oxygen gas mixture; investigate the mechanisms that limit expiratory airflow: intrinsic airway obstruction vs loss of lung elastic recoil; determine the extent of asthma and distribution of emphysema

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov